microRNA-199a is able to reverse cisplatin resistance in human ovarian cancer cells through the inhibition of mammalian target of rapamycin

被引:63
作者
Wang, Zhongxian [1 ,2 ]
Ting, Zhou [3 ]
Li, Ya [3 ]
Chen, Gang [3 ]
Lu, Yunping [3 ]
Hao, Xing [3 ]
机构
[1] China Three Gorges Univ, Dept Obstet & Gynecol, Coll Clin Med Sci 1, Yichang, Hubei, Peoples R China
[2] China Three Gorges Univ, Yichang Cent Peoples Hosp, Yichang, Hubei, Peoples R China
[3] Huazhong Univ Sci & Technol, Dept Obstet & Gynecol, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China
关键词
microRNA-199a; mammalian target of rapamycin; cisplatin resistance; ovarian cancer cells; MTOR; SENSITIVITY; EXPRESSION; APOPTOSIS; SURVIVAL; PATHWAY;
D O I
10.3892/ol.2013.1448
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
microRNAs (miRNAs/miRs) may have a crucial function in tumor metastasis through the regulation of a plethora of signaling pathways. Increasing evidence has shown that miR-199a is important in regulating the tumor metastasis of ovarian cancer, although the precise biological function of miR-199a is unclear at present. In the current study, it was observed that the expression levels of miR-199a were higher in OV2008 cells compared with C13* cells. However, lower levels of mammalian target of rapamycin (mTOR) protein were detected by western blotting in the OV2008 cells compared with the C13* cells. The miR-199a levels were increased in the C13* cells using miR-199a mimics and the mTOR levels were observed to decrease. This may have resulted in a reversal of cisplatin resistance in the C13* cells. To test this hypothesis, the Renilla luciferase reporter gene system was used to analyze the mTOR levels. The results indicated that the expression levels of mTOR were significantly blocked by the increased miR-199a levels. When the miR-199a inhibitor was applied to decrease the miR-199a levels, it was observed that the mTOR expression levels were increased, while cisplatin-induced apoptosis was decreased in the OV2008 cells. The study concludes that miR-199a is able to reverse cisplatin resistance in human ovarian cancer cells through the inhibition of mTOR and that mTOR may be the target of miR-199a during this process.
引用
收藏
页码:789 / 794
页数:6
相关论文
共 19 条
  • [1] Castedo M, 2002, CELL DEATH DIFFER, V9, P99, DOI 10.1038/sj/cdd/4400978
  • [2] Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope
    Castedo, M
    Roumier, T
    Blanco, J
    Ferri, KF
    Barretina, J
    Tintignac, LA
    Andreau, K
    Perfettini, JL
    Amendola, A
    Nardacci, R
    Leduc, P
    Ingber, DE
    Druillennec, S
    Roques, B
    Leibovitch, SA
    Vilella-Bach, M
    Chen, J
    Este, JA
    Modjtahedi, N
    Piacentini, M
    Kroemer, G
    [J]. EMBO JOURNAL, 2002, 21 (15) : 4070 - 4080
  • [3] Cho William C S, 2009, Expert Rev Mol Diagn, V9, P411, DOI 10.1586/erm.09.34
  • [4] MiR-199a-3p Regulates mTOR and c-Met to Influence the Doxorubicin Sensitivity of Human Hepatocarcinoma Cells
    Fornari, Francesca
    Milazzo, Maddalena
    Chieco, Pasquale
    Negrini, Massimo
    Calin, George Adrian
    Grazi, Gian Luca
    Pollutri, Daniela
    Croce, Carlo Maria
    Bolondi, Luigi
    Gramantieri, Laura
    [J]. CANCER RESEARCH, 2010, 70 (12) : 5184 - 5193
  • [5] Foster H, 2010, ANTICANCER RES, V30, P3529
  • [6] Identification of miRNomes in Human Liver and Hepatocellular Carcinoma Reveals miR-199a/b-3p as Therapeutic Target for Hepatocellular Carcinoma
    Hou, Jin
    Lin, Li
    Zhou, Weiping
    Wang, Zhengxin
    Ding, Guoshan
    Dong, Qiongzhu
    Qin, Lunxiu
    Wu, Xiaobing
    Zheng, Yuanyuan
    Yang, Yun
    Tian, Wei
    Zhang, Qian
    Wang, Chunmei
    Zhang, Qinghua
    Zhuang, Shi-Mei
    Zheng, Limin
    Liang, Anmin
    Tao, Wenzhao
    Cao, Xuetao
    [J]. CANCER CELL, 2011, 19 (02) : 232 - 243
  • [7] Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain
    Li, X
    Alafuzoff, I
    Soininen, H
    Winblad, B
    Pei, JJ
    [J]. FEBS JOURNAL, 2005, 272 (16) : 4211 - 4220
  • [8] PI3K/AKT/mTOR Inhibitors In Ovarian Cancer
    Mazzoletti, M.
    Broggini, M.
    [J]. CURRENT MEDICINAL CHEMISTRY, 2010, 17 (36) : 4433 - 4447
  • [9] MicroRNA expression profiles in serous ovarian carcinoma
    Nam, Eun Ji
    Yoon, Heejei
    Kim, Sang Wun
    Kim, Hoguen
    Kim, Young Tae
    Kim, Jae Hoon
    Kim, Jae Wook
    Kim, Sunghoon
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (09) : 2690 - 2695
  • [10] Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells
    Peng, Dong-Jun
    Wang, Juan
    Zhou, Jun-Ying
    Wu, Gen Sheng
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 394 (03) : 600 - 605